The gene PRAME (preferentially expressed antigen in melanoma) is mapped to human chromosome 22q11. The encoded protein belongs to the cancer D testis antigen family. It is a tumor-associated antigen. PRAME has very low or no expression in normal tissues. PRAME protein interacts with:
•CUL2 (anti-CUL2 HPA024578)
•TCEB1 (anti-TCEB1 HPA078113)
•TCEB2 (anti-TCEB2 SAB1409726)
Synonyms: Prame Antibody; Prame Antibody - Anti-PRAME antibody produced in rabbit; Anti-Ct130; Anti-Mape; Anti-Preferentially expressed antigen in melanoma
Storage: -20C
Application: All Prestige Antibodies(R)Powered by Atlas Antibodies is developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org). Each antibody is tested by immunohistochemistry against hundreds of normal and disease tissues. These images can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit sigma.com/prestige.Anti-PRAME antibody produced in rabbit has been used in western blotting, immunohistochemistry and immunofluorescence.
Biochem Physiol Actions: PRAME (preferentially expressed antigen in melanoma) is overexpressed in malignant cells, including primary and metastatic melanomas, acute and chronic leukaemias, Hodgkin's lymphoma, breast cancer and head and neck squamous cell carcinomas. In AML (acute myeloid leukemia), high levels of PRAME are associated with lower relapse rate and high chances of disease-free survival. PRAME also plays a role in the retinol pathway. It modulates the metabolism of all-trans retinol (vitamin A) and its active metabolites, referred to as retinoids. It is a repressor of retinoic acid receptor signaling.
Legal Information: Prestige Antibodies is a registered trademark of Sigma-Aldrich Co. LLC